ARMODAFINIL
Total Payments
$16,139
Transactions
5
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $8,069 | 2 | 2 |
| 2023 | $8,070 | 3 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16,139 | 5 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| The Nuvigil (Armodafinil) Tablets [C-IV]/Provigil (Modafinil) Tablets [C-IV] Pregnancy Registry | Teva Pharmaceuticals USA, Inc. | $16,139 | 2 |
Ad
Manufacturing Companies
- Teva Pharmaceuticals USA, Inc. $16,139
Product Information
- Type Drug
- Total Payments $16,139
- Total Doctors 2
- Transactions 5
About ARMODAFINIL
ARMODAFINIL is a drug associated with $16,139 in payments to 2 healthcare providers, recorded across 5 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2023 to 2024. In 2024, $8,069 was paid across 2 transactions to 2 doctors.
The most common payment nature for ARMODAFINIL is "Unspecified" ($16,139, 100.0% of total).
ARMODAFINIL is associated with 1 research study, including "The Nuvigil (Armodafinil) Tablets [C-IV]/Provigil (Modafinil) Tablets [C-IV] Pregnancy Registry" ($16,139).